Olufunmilayo Olopade to Neoplasms
This is a "connection" page, showing publications Olufunmilayo Olopade has written about Neoplasms.
Connection Strength
2.863
-
Cancer Genetic Services in a Low- to Middle-Income Country: Cross-Sectional Survey Assessing Willingness to Undergo and Pay for Germline Genetic Testing. JCO Glob Oncol. 2023 02; 9:e2100140.
Score: 0.299
-
Precision oncology: Directing genomics and pharmacogenomics toward reducing cancer inequities. Cancer Cell. 2021 06 14; 39(6):730-733.
Score: 0.266
-
Black Lives Matter Worldwide: Retooling Precision Oncology for True Equity of Cancer Care. Cell Rep Med. 2020 08 25; 1(5):100079.
Score: 0.253
-
Implementing oncology clinical trials in Nigeria: a model for capacity building. BMC Health Serv Res. 2020 Aug 03; 20(1):713.
Score: 0.252
-
Genetic Ancestry May Influence the Evolutionary Trajectory of Cancers. Cancer Cell. 2018 10 08; 34(4):529-530.
Score: 0.222
-
Cancer Susceptibility Genetic Testing in a High-Risk Cohort of Urban Ashkenazi Jewish Individuals. J Genet Couns. 2018 12; 27(6):1405-1410.
Score: 0.217
-
Tumor genome analysis includes germline genome: are we ready for surprises? Int J Cancer. 2015 Apr 01; 136(7):1559-67.
Score: 0.166
-
Interpretation of genome-wide association study results. Oncology (Williston Park). 2010 Jun; 24(7):643, 646.
Score: 0.124
-
Disparities in genetic testing: thinking outside the BRCA box. J Clin Oncol. 2006 May 10; 24(14):2197-203.
Score: 0.094
-
Confronting genetic testing disparities: knowledge is power. JAMA. 2005 Apr 13; 293(14):1783-5.
Score: 0.087
-
The impact of site-specific digital histology signatures on deep learning model accuracy and bias. Nat Commun. 2021 07 20; 12(1):4423.
Score: 0.067
-
Comparison of DCE-MRI of murine model cancers with a low dose and high dose of contrast agent. Phys Med. 2021 Jan; 81:31-39.
Score: 0.065
-
Cancer Risks Associated With Germline PALB2 Pathogenic Variants: An International Study of 524 Families. J Clin Oncol. 2020 03 01; 38(7):674-685.
Score: 0.060
-
Genetic testing for susceptibility to cancer. Task Force on Cancer Genetics Education. JAMA. 1998 May 27; 279(20):1612-3.
Score: 0.054
-
Genetic testing of families with hereditary diseases. JAMA. 1996 Oct 09; 276(14):1138-9; author reply 1140.
Score: 0.048
-
An Evaluation of Psychosocial and Religious Belief Differences in a Diverse Racial and Socioeconomic Urban Cancer Population. J Racial Ethn Health Disparities. 2017 04; 4(2):140-148.
Score: 0.046
-
Closing the Cancer Divide Through Ubuntu: Information and Communication Technology-Powered Models for Global Radiation Oncology. Int J Radiat Oncol Biol Phys. 2016 Mar 01; 94(3):440-9.
Score: 0.045
-
Construction of a 2.8-megabase yeast artificial chromosome contig and cloning of the human methylthioadenosine phosphorylase gene from the tumor suppressor region on 9p21. Proc Natl Acad Sci U S A. 1995 Jul 03; 92(14):6489-93.
Score: 0.044
-
Detection of CDKN2 deletions in tumor cell lines and primary glioma by interphase fluorescence in situ hybridization. Cancer Res. 1995 Mar 01; 55(5):984-8.
Score: 0.043
-
National survey of US oncologists' knowledge, attitudes, and practice patterns regarding herb and supplement use by patients with cancer. J Clin Oncol. 2014 Dec 20; 32(36):4095-101.
Score: 0.042
-
Development of a tiered and binned genetic counseling model for informed consent in the era of multiplex testing for cancer susceptibility. Genet Med. 2015 Jun; 17(6):485-92.
Score: 0.042
-
Treatment of cancer in sub-Saharan Africa. Lancet Oncol. 2013 Apr; 14(4):e158-67.
Score: 0.038
-
Transforming epidemiology for 21st century medicine and public health. Cancer Epidemiol Biomarkers Prev. 2013 Apr; 22(4):508-16.
Score: 0.038
-
Mapping of the shortest region of overlap of deletions of the short arm of chromosome 9 associated with human neoplasia. Genomics. 1992 Oct; 14(2):437-43.
Score: 0.037
-
When parents disclose BRCA1/2 test results: their communication and perceptions of offspring response. Cancer. 2012 Jul 01; 118(13):3417-25.
Score: 0.035
-
Malignant effusions. CA Cancer J Clin. 1991 May-Jun; 41(3):166-79.
Score: 0.033
-
Cancer survivorship care: exploring the role of the general internist. J Gen Intern Med. 2009 Nov; 24 Suppl 2:S495-500.
Score: 0.030
-
Translational integrity and continuity: personalized biomedical data integration. J Biomed Inform. 2009 Feb; 42(1):100-12.
Score: 0.027
-
Disparities in cancer care: a worldwide perspective and roadmap for change. J Clin Oncol. 2006 May 10; 24(14):2135-6.
Score: 0.023
-
Identification of a 1.2 Kb cDNA fragment from a region on 9p21 commonly deleted in multiple tumor types. Cancer Genet Cytogenet. 2001 Sep; 129(2):93-101.
Score: 0.017
-
Lack of evidence for a polymorphism at codon 160 of human O6-alkylguanine-DNA alkyltransferase gene in normal tissue and cancer. Clin Cancer Res. 1999 Jan; 5(1):209-13.
Score: 0.014
-
The American Society of Clinical Oncology position on genetic testing: implications for health care providers: workshop no. 4. Cancer. 1997 Aug 01; 80(3 Suppl):632-4.
Score: 0.013
-
Building capacity for sustainable research programmes for cancer in Africa. Nat Rev Clin Oncol. 2014 May; 11(5):251-9.
Score: 0.010
-
EDD, the human orthologue of the hyperplastic discs tumour suppressor gene, is amplified and overexpressed in cancer. Oncogene. 2003 Aug 07; 22(32):5070-81.
Score: 0.005
-
Mapping a putative tumor suppressor gene on chromosome 9 bands p21-p22 with microdissection probes. Genomics. 1994 Nov 15; 24(2):211-7.
Score: 0.003
-
Structure of the human type-I interferon gene cluster determined from a YAC clone contig. Genomics. 1994 Aug; 22(3):540-52.
Score: 0.003